MAPT and Alzheimer disease: The ATN is designed to provide a structured and unbiased categorization of the AD continuum and is based upon biological/molecular changes identified by post-mortem examination or by biomarkers (i.e. amyloid – ‘A,’ tau – ‘T,’ and neurodegeneration – ‘N’ Jack et al., 2018).